A clinical trial sponsored by the University of Baghdad has been announced to evaluate the efficacy of microneedling alone and in combination with injectable hyaluronic acid for gingival augmentation in patients with thin gingival phenotype. This study aims to address a growing need for evidence-based solutions in oral health rehabilitation, particularly for individuals with thin gingival biotypes.
This trial is currently in the planning stages and listed as “Not yet recruiting.” The research will potentially have implications for dental professionals, medical device manufacturers, and regulatory stakeholders seeking innovative approaches to gum augmentation.
What does the study aim to achieve?
Individuals with thin gingival biotype face unique challenges such as increased susceptibility to gum recession, periodontal disease, and compromised dental aesthetics. This clinical trial seeks to determine whether microneedling alone or in combination with hyaluronic acid injections can enhance gingival augmentation. The primary endpoint will likely include measurements of gingival tissue thickness and overall periodontal health improvements.
The researchers intend to focus on two intervention categories: microneedling (MN) as a standalone procedure and microneedling combined with injectable hyaluronic acid (MN + HA). By evaluating these approaches, the trial could provide data critical for future device development and regulatory filings.
What is the technology involved?
Microneedling is a minimally invasive procedure that involves creating micro-perforations in the skin or tissue to stimulate natural healing and regeneration. When combined with hyaluronic acid—a biocompatible and widely used dermal filler known for its hydrating and wound-healing properties—the technique may enhance gingival volume and tissue resilience.
These procedures are being carefully scrutinized to determine their safety, performance, and reliability in meeting their intended therapeutic purpose, all consistent with the principles of medical device regulation. If successful, the methodology may become a transformative option for gingival augmentation.
Who could benefit from this research?
The study’s outcomes will be particularly relevant to dental practitioners specializing in periodontology and oral health restoration. Moreover, manufacturers of medical devices focusing on soft tissue augmentation could find the results informative for product development and clinical validation. Regulatory agencies monitoring advancements in combination medical-device therapies could also find the data helpful for future evaluations of such procedures.
Importantly, patients with thin gingival biotype may gain access to new, less invasive treatment options. This could represent a significant quality-of-life improvement, especially for those affected by gum recession or periodontal health issues.
Frequently Asked Questions
-
1. Is this treatment currently available?
No, the procedures under evaluation—microneedling with and without hyaluronic acid injection—are still under clinical investigation. -
2. Who is conducting this study?
The study is sponsored by the University of Baghdad. -
3. When will recruitment begin?
As of now, the trial is listed as “Not yet recruiting.” An official recruitment date has not been announced.
Conclusion and Takeaways
The upcoming clinical trial on microneedling and hyaluronic acid injections for gingival augmentation may offer meaningful contributions to oral health science. Professionals and stakeholders in the dental and medical device fields should keep a close eye on the progress of this trial for insights and potential regulatory impacts.
Disclaimer
This article is for informational purposes only and is intended for professionals in the clinical, quality, and regulatory fields. It does not constitute legal, regulatory, or medical advice.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07317856?term=medical+device